Skip to main content
Quest Diagnostics

Development and Validation of a High Throughput SARS-CoV-2 Whole Genome Sequencing Workflow in a Clinical Laboratory

Development and validation of a high throughput SARS-CoV-2 whole genome sequencing workflow in a clinical laboratory

Authors: Rosenthal SH, Gerasimova A, Ruiz-Vega R, Livingston K, Kagan RM, Liu Y, Anderson B, Owen R, Bernstein L, Smolgovsky A, Xu D, Chen R, Grupe A, Tanpaiboon P, Lacbawan F.

Citation: Sci Rep. 2022 Feb 8;12(1):2054. doi: 10.1038/s41598-022-06091-0.

Specialties: Infectious Disease, Genetics, COVID-19

Download key summary

Related content

Publication
Assessing vulnerability to COVID 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Publication
Comparison of SARS-CoV-2 RT-PCR Ct values across multiple assays with different targets
Publication
Impact of the COVID-19 Pandemic on Blood Lead Testing in Children in the United States

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.